UTHealth Expert List
Charles Cox, M.D.
- George & Cynthia Mitchell Distinguished Chair in Neurosciences, Department of Pediatric Surgery, UTHealth Medical School
- Director of the Pediatric Surgical Translational Laboratories and Pediatric Program in Regenerative Medicine, UTHealth Medical School
- Director of the Pediatric Trauma Program, UTHealth Medical School/Children’s Memorial Hermann Hospital
- Co-director, Texas Trauma Institute
Charles S. Cox, Jr., M.D., specializes in treatment and research surrounding stem cell therapy for traumatic brain injury and related neurological injuries (hypoxic-ischemic encephalopathy, stroke, spinal cord injury). He has published results of the first acute, autologous cell therapy treatment, Phase I study for traumatic brain injury in children and has begun another trial using cord blood stem cells.
Previous Interview: http://bit.ly/q5kbrz
Sean Savitz, M.D.
- Director, Vascular Neurology Program, UTHealth Medical School
- Professor, Department of Neurology, UTHealth Medical School
Sean I. Savitz, M.D., specializes in the treatment and research of acute stroke. His research includes using autologous stem cells after acute stroke given intravenously and subacute stroke given by intra-carotid administration; using umbilical cord tissue-derived cells for acute ischemic stroke; and using tPA in patients who wake up with symptoms of stroke.
Previous Interview: http://bit.ly/n6DlV5
Rick Wetsel, Ph.D.
- Professor of Molecular Medicine and the William S. Kilroy Sr. Chair in Pulmonary Disease, UTHealth Medical School
- Director of the Irma Gigli & Hans J. Mueller-Eberhard Research Center for Immunology and Autoimmune Diseases at The Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (IMM), a part of the UTHealth Medical School
Rick A. Wetsel, Ph.D. is leading a research program on the use of human embryonic stem cells to develop a transplantable source of lung cells that could be used to treat lung diseases such as acute respiratory distress syndrome and emphysema. Wetsel's team also is using these cells for gene therapy for inherited genetic defects affecting the lungs including cystic fibrosis and surfactant protein deficiency.
Previous Interview: http://bit.ly/qx0wMK